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Editorial on the Research Topic
TAVI and the Challenges Ahead
Transcatheter aortic valve implantation (TAVI) was introduced in 2002 and significant efforts
in research and innovation have subsequently positioned this procedure as an important
breakthrough in cardiovascular medicine (1). TAVI has become the preferred treatment strategy
for symptomatic severe aortic stenosis (AS) among patients deemed to be at excessive- or high-risk
for conventional surgical aortic valve replacement (SAVR) and is an alternative to surgery among
intermediate- and low surgical-risk patients (2, 3).
Two decades of device iteration, refinement of procedural technique, growing operator
experience, and enhanced patient selection, have significantly reduced peri-procedural
complications and improved short and mid-term clinical outcomes. Central to these advances has
been the concept of the Heart Team, a group of interdisciplinary healthcare professionals that each
bring their experience to bear on the management of the individual patient with complex structural
heart disease (1). Together the institutional Heart Team weight the anatomic, physiologic, and
psychosocial aspects of each patient to develop an individualized treatment plan.
Despite the aforementioned success of TAVI, there remain important challenges to further
streamline the procedure, reduce costs, and improve patient outcomes. In particular, extending
TAVI to younger and lower risk patients in the aftermath of two key industry-sponsored
low risk trials requires particular attention. Relevant topics for discussion include the relative
merits/drawbacks of TAVI compared to SAVR, the impact and potential mitigation strategies for
periprocedural stroke and permanent pacemaker implantation, the use of oral anticoagulation after
TAVI, and the question of long-term transcatheter heart valve durability.
The present collection explores current and future challenges of TAVI, includes articles from
a diagnostic and technical perspectives, and provides guidance on patient and vascular access
selection, the importance and application of multimodal imaging, and outlines a pathway toward
procedure simplification. The risk of cerebrovascular events and how to prevent them, the impact
of concomitant mitral regurgitation and post-TAVI conduction abnormalities are explored and
future directions in the TAVI space are discussed, including extension of the technology to younger
patients, low-risk cohorts, and potentially, the role of the technology in patients with moderate
aortic stenosis and heart failure.
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PRE-PROCEDURAL PLANNING AND
TECHNIQUE
Advances in pre-procedural planning and refinement in
procedural techniques have greatly improved clinical outcome.
These developments are elegantly presented by Akodad
and Lefèvre through a step-by-step approach starting with
the indisputable need for a pre-TAVI multi-slice computed
tomography (CT) for planning vascular access, valve type and
size selection, and procedural execution. The authors describe
their local experience of the benefits of fully percutaneous access,
secondary radial access, conscious sedation rather than general
anesthesia, rapid pacing over the left ventricular guide wire,
implantation without pre-dilatation, and early discharge with
limited use of the intensive care unit—restricted to patients with
low-risk of post-procedural complications.
Biasco et al. dedicate a comprehensive review of vascular
access sites for TAVI. The transfemoral approach is considered
to be the first choice by guideline and consensus documents
but alternative vascular access remains an important option in
selected cases. Traditional alternate access routes include the
transapical and transaortic approaches with novel and often
fully percutaneous options including transaxillary, transcarotid,
and transcaval accesses. The authors compare procedural
success and clinical outcomes among alternate vascular
access routes, underscoring that no prospective head-to-head
comparisons exist.
Careful pre-procedural planning is crucial for successful
TAVI. The role of MSCT imaging is particularly important
in the setting of TAVI for the treatment of bicuspid aortic
valve (BAV) disease. Das and Puri comprehensively summarize
current data on imaging and interventional considerations in
BAV. The authors highlight that asymmetric valve leaflets, the
presence of a raphe, and heavy calcification among patients
with BAV tend to yield more complex procedures. BAV patients
undergoing TAVImay have a higher risk of valvemalposition and
frame underexpansion and hence increased rates of moderate
to severe paravalvular regurgitation. Pre and post-dilatation can
lead to aortic annular rupture if balloon sizing is excessive
and the risk of ostial coronary artery occlusion and aortic
dissection may be higher in patients with BAV undergoing TAVI.
Recent device iteration and clinical evidence have documented
improving procedural success and clinical outcomes among BAV
patients, and prospective randomized controlled trials compared
to surgery are called-for in this field.
O’Sullivan et al., in an original publication discuss pulmonary
hypertension (PH) in patients undergoing TAVI. PH is a
common finding in patients with severe symptomatic AS and
has been associated with worse clinical outcomes. Among
TAVI candidates, most PH is post-capillary in nature and
thus associated with an increased left ventricular end-diastolic
pressure. The gold standard assessment is with right heart
catheterization however echocardiography provides indirect
measurements of the pulmonary pressures. Pre-TAVI CT can
also contain important clues that can be used to screen for PH.
O’Sullivan et al. describe several potential markers, including
a cut-off for the ratio between the pulmonary artery and the
aortic artery diameters, which may help screening of patients
undergoing TAVI.
CURRENT CHALLENGES
Armijo et al. have meticulously addressed the incidence, timing,
relevance, and prevention of cerebrovascular events (CVE) after
TAVI. In the original PARTNER tirals, CVE were thought to
be higher after TAVI compared to SAVR (ascertainment bias),
current suggests stroke may be more common after SAVR. In
a meta-analysis including >72,000 patients, the 30-day post-
TAVI stroke rate was 3.3% (4). Importantly, the majority of these
events are disabling and profoundly impacting patient quality of
life. Up to 95% of procedural CVEs are ischaemic and generally
are related to an embolic source, including the aortic wall,
calcified aortic valves, and thrombotic material. Sub-acute CVEs
are usually local thrombotic events (valve-related) or caused by
atrial arrhythmia. Antithrombotic strategies as well as cerebral
embolic protection devices (CEPD) have the potential to reduce
the frequency and impact of these events and several ongoing
randomized trials in this space are discussed by the authors.
Along these lines, Demir et al. present a rigorous review
of CEPD, which were introduced to mitigate the risk of CVE
during the TAVI procedure. These devices capture or deflect
embolic particles away from the supra-aortic vessels and have the
potential to reduce CVEs. The authors summarize the available
evidence for the Claret CEPD (Boston Scientific) and for the
TriGuard (Keystone Heart, Venus MedTech) and describe a
range of other devices in development. The Claret device is a dual
filter deployed in the brachiocephalic and left common carotid
arteries, but leaving the left vertebral artery unprotected. The
largest trial with CEPD (n= 363) to date, failed to demonstrate a
significant reduction in the total new lesion volume on diffusion
weighted cerebral MRI in the protected territories compared to
placebo (5). However, further randomized trials of this device
with clinical stroke as a powered endpoint are ongoing. The
TriGuard 3 CEP is a mesh filter that is positioned across the
three cerebral vessels and has been recently awarded CE-mark
approval. Initial data have shown reduction of new cerebral
lesions as well as lower rates of clinical CVE.
Mitral regurgitation (MR) is a common echocardiographic
finding in the elderly, and moderate or severe MR affects ∼20%
of high-risk patients undergoing TAVI. Stähli et al. detail that
moderate or severeMR is associated with worse clinical outcomes
post-TAVI; however, it remains unsettled whether a direct cause-
effect relationship exists. Importantly, in up to 60% of patients
with MR undergoing TAVI, the severity of MR is improves at
30 days post TAVI, a finding that is hampered in patients with
atrial fibrillation or severe PH. The authors describe transcatheter
treatment options for residual post TAVI moderate to severe
MR as well as important considerations for the timing of post-
TAVI management of MR. The MitraClip (Abbott Vascular)
has recently gained attention after the results of the COAPT
trial which showed a significant reduction of mortality and
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hospitalizations in heart failure patients with moderate to severe
MR, when compared with medical therapy (6).
Conduction abnormalities remain a common complication
after TAVI due to the anatomical vicinity of the conduction
system and the landing zone of the bioprosthetic valve. Mangieri
et al. discuss in-depth the frequency and impact of new-onset left
bundle branch block (LBBB) and other conduction disturbance
and the need for permanent pacemaker (PPM) implantation
post-TAVI. The type of device utilized, the depth of implantation,
and the need of pre- and post-dilation to reduce paravalvular
regurgitation are major determinants. Acute TAVI-related injury
to the conduction system may cause LBBB in ∼10–30% of
patients and complete atrioventricular block (AVB) in∼10–30%.
Importantly, LBBB may resolve in up to 85% of patients while
complete AVBmay resolve in up to 50%. The decision to implant
a PPM therefore, should be couple with sufficient in-hospital
telemetry monitoring.
FUTURE DIRECTIONS
At the 2019 American College of Cardiology Annual Scientific
Meeting, data from two large randomized controlled trials in
low-risk cohorts were presented (2, 3). Balloon-expandable and
self-expandable THV devices were non-inferior to SAVR for the
pre-specified endpoints, and hence these trials will have far-
reaching implications on current and future TAVI practice. The
cohorts treated in these trials were almost 10 years younger
than those included in high-risk cohorts. As De Backer and
Søndergaard predicted in this section, the expansion to younger
populations highlights the need for understanding the use of
TAVI in patients with BAV: this morphology accounts for up to
50% of severe AS cases in patients <75 years of age. Long-term
valve durability data is being collected, however, given that BAV
has been largely excluded from RCTs, high quality registries or
dedicated RCTs are required to further characterize the durability
of TAVI prosthesis in BAV morphology. Furthermore, rates of
complications may be distinctive in younger in BAV cohorts and
merits careful investigation.
Voigtländer and Seiffert diligently explain this shift in
focus from the early narrow high-risk TAVI cohort to the
current broad all levels of surgical risk TAVI population.
Patient has to date been classified according to the Society of
Thoracic Surgeons Predicted Risk of Mortality (STS-PROM)
at 30 days; being <4% low, 4 to 8% intermediate, and >8%
high risk patients. However, this score does not include other
important factors such as active malignancy, frailty, porcelain
aorta, chest wall radiation, liver cirrhosis, or neurological
impairment, which are important for the Heart Team decision-
making. Other factors favoring TAVI include age >75, prior
cardiac surgery, restricted mobility or anticipated prolonged
rehabilitation, transfemoral access, severe chest deformation, or
prosthesis-patient mismatch. The authors present highlights of
data stemming from RCTs and registries that support the use
of TAVI in intermediate-risk and data being gathered for low-
risk cohorts.
Finally, Spitzer et al. open a new chapter for TAVI by
providing the rationale for exploring this breakthrough therapy
in patients with moderate AS in the presence of reduced
left ventricular ejection fraction (LVEF). This new therapeutic
target represents 0.8% of patients referred for echocardiographic
assessment, and without intervention have been associated with
a high rate of mortality and heart failure hospitalizations.
The epidemiology, natural history, and patient characteristics
are discussed, as well as the challenges in echocardiographic
diagnosis of moderate AS in patient with reduced LVEF. An
ongoing trial (NCT02661451) is testing the role of TAVI in this
patient population. If proven successful, implementation of new
clinical pathways to identify and derive these patients to a TAVI
operator in a timely manner will be required, since currently
patients with moderate AS are not considered a target of therapy.
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